CHMP recommendation brings new hope for patients
Category: News
VYVGART could be the first CIDP drug with a novel mechanism in 30 years
Cambridge firm in-licenses two oncology programmes
MHRA authorises drug for adults with rare heart muscle damage
It is hoped that the MAGIC-I study will support earlier diagnosis and personalised treatment
The university has been awarded a £1m grant from LifeArc and Muscular Dystrophy UK
The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine
More than 37 million adults in the US are affected by migraine
European Commission grants authorisation for Eisai and Biogen therapy
New real-world data reinforce treatment benefit